colorectal cancer
Federica Facciotti, from University of Milano Bicocca, focuses on how the gut microbiota interacts with immune activation, shaping both chronic inflammatory intestinal disorders and oncology, particularly colorectal cancer.
Profiling the human gut microbiota at the subspecies level, rather than at the species- or strain-level, provides more reproducible insights into how specific bacteria influence health and disease.
Nanoparticle-based approaches are a promising strategy for treating colorectal cancer.
Genetic factors can influence tumor-associated microbes, offering insights into colorectal cancer progression and potential therapeutic targets.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
The microbiota plays a protective role against colorectal cancer by regulating Snhg9.
The findings support the idea that the gut microbiota modulates immune responses, suggesting new avenues for cancer treatment.
A recent study demonstrated causation between microbial DCA metabolism and anti-tumor CD8+ T cell response in colorectal cancer.
By providing insights into how the gut microbiota influences cancer susceptibility, the findings may help to develop new therapies or dietary interventions.
